Ipsen Sells the North American1 Development and Marketing Rights for Apokyn® to Britannia Pharmaceuticals Limited, Achieving a Key Milestone in the Execution of its New North American Strategy
11/3/2011 6:20:55 AM
More...
|
Ipsen Sells the North American1 Development and Marketing Rights for Apokyn® to Britannia Pharmaceuticals Limited, Achieving a Key Milestone in the Execution of its New North American strategy
11/2/2011 12:05:01 PM
More...
|
Kyowa Hakko Kogyo Co., Ltd. To Introduce Self-Injectable Drug For Treating Parkinson's Disease From Britannia Pharmaceuticals Limited
2/23/2006 1:23:00 PM
More...
|
Britannia Pharmaceuticals Limited Simplifies Apomorphine Delivery With New Pre-Filled Syringe
10/19/2005 5:12:12 PM
More...
|
airPharma Signs Agreement With Britannia Pharmaceuticals Limited To Bring Novel Asthma Treatment To Market
10/19/2005 5:12:07 PM
More...
|
Britannia Pharmaceuticals Limited Expands Nasal Powder Program With New Production Capability
10/19/2005 5:11:31 PM
More...
|
Bertek Pharmaceuticals, Subsidiary Of Mylan Laboratories Inc. (MYL) , Receives FDA Approval For Parkinson’s Disease Treatment (Previously Announced)
10/19/2005 5:11:17 PM
More...
|
Otsuka Pharmaceuticals UK Ltd Selects Britannia Pharmaceuticals Limited To Distribute Adacolumn In The United Kingdom; Novel Treatment For Inflammatory Related Diseases Provides A Significant Alternative To Other Pharmaceutical Therapies
10/19/2005 5:10:55 PM
More...
|
Britannia Pharmaceuticals Limited Signs Agreement With US WorldMeds, LLC To Bring First Non-Opiate Drug Addiction Treatment To The U.S.
10/19/2005 5:10:48 PM
More...
|
Britannia Pharmaceuticals Limited Closes 2003 With Several New Partnership Agreements And Significant Clinical Progress
10/19/2005 5:09:45 PM
More...
|